The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Severe Acute Respiratory Syndrome (SARS) Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Severe Acute Respiratory Syndrome (SARS) Therapeutics in various end use industries. The expanding demands from the Hospital, Clinic and Research Center,, are propelling Severe Acute Respiratory Syndrome (SARS) Therapeutics market. CEL-1000, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the D-3252 segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Severe Acute Respiratory Syndrome (SARS) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Severe Acute Respiratory Syndrome (SARS) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Severe Acute Respiratory Syndrome (SARS) Therapeutics covered in this report include CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC and Protein Sciences Corporation, etc.
The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Inovio Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Novavax, Inc.
Phelix Therapeutics, LLC
Protein Sciences Corporation
Global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, Segment by Type:
CEL-1000
D-3252
FDX-000
INO-4500
LCA-60
Others
Global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, by Application
Hospital
Clinic
Research Center
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Severe Acute Respiratory Syndrome (SARS) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Severe Acute Respiratory Syndrome (SARS) Therapeutics in various end use industries. The expanding demands from the Hospital, Clinic and Research Center,, are propelling Severe Acute Respiratory Syndrome (SARS) Therapeutics market. CEL-1000, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the D-3252 segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Severe Acute Respiratory Syndrome (SARS) Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Severe Acute Respiratory Syndrome (SARS) Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Severe Acute Respiratory Syndrome (SARS) Therapeutics covered in this report include CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC and Protein Sciences Corporation, etc.
The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Inovio Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Novavax, Inc.
Phelix Therapeutics, LLC
Protein Sciences Corporation
Global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, Segment by Type:
CEL-1000
D-3252
FDX-000
INO-4500
LCA-60
Others
Global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, by Application
Hospital
Clinic
Research Center
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Severe Acute Respiratory Syndrome (SARS) Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Severe Acute Respiratory Syndrome (SARS) Therapeutics
1.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Overview
1.1.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Scope
1.1.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Status and Outlook
1.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2018-2029)
1.4 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2029)
1.6.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2029)
1.6.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2029)
1.6.4 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2018-2029)
2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Type
2.1 Introduction
2.1.1 CEL-1000
2.1.2 D-3252
2.1.3 FDX-000
2.1.4 INO-4500
2.1.5 LCA-60
2.1.6 Others
2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Type (2018-2029)
3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Research Center
3.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Breakdown by Application (2018-2029)
4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Competition Analysis by Players
4.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics as of 2022)
4.3 Date of Key Players Enter into Severe Acute Respiratory Syndrome (SARS) Therapeutics Market
4.4 Global Top Players Severe Acute Respiratory Syndrome (SARS) Therapeutics Headquarters and Area Served
4.5 Key Players Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 CEL-SCI Corporation
5.1.1 CEL-SCI Corporation Profile
5.1.2 CEL-SCI Corporation Main Business
5.1.3 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.1.4 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 CEL-SCI Corporation Recent Developments
5.2 GeneCure LLC
5.2.1 GeneCure LLC Profile
5.2.2 GeneCure LLC Main Business
5.2.3 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.2.4 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 GeneCure LLC Recent Developments
5.3 Humabs BioMed SA
5.3.1 Humabs BioMed SA Profile
5.3.2 Humabs BioMed SA Main Business
5.3.3 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.3.4 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Inovio Pharmaceuticals, Inc. Recent Developments
5.4 Inovio Pharmaceuticals, Inc.
5.4.1 Inovio Pharmaceuticals, Inc. Profile
5.4.2 Inovio Pharmaceuticals, Inc. Main Business
5.4.3 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.4.4 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Inovio Pharmaceuticals, Inc. Recent Developments
5.5 Nanotherapeutics, Inc.
5.5.1 Nanotherapeutics, Inc. Profile
5.5.2 Nanotherapeutics, Inc. Main Business
5.5.3 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.5.4 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Nanotherapeutics, Inc. Recent Developments
5.6 Novavax, Inc.
5.6.1 Novavax, Inc. Profile
5.6.2 Novavax, Inc. Main Business
5.6.3 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.6.4 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Novavax, Inc. Recent Developments
5.7 Phelix Therapeutics, LLC
5.7.1 Phelix Therapeutics, LLC Profile
5.7.2 Phelix Therapeutics, LLC Main Business
5.7.3 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.7.4 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Phelix Therapeutics, LLC Recent Developments
5.8 Protein Sciences Corporation
5.8.1 Protein Sciences Corporation Profile
5.8.2 Protein Sciences Corporation Main Business
5.8.3 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Products, Services and Solutions
5.8.4 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Protein Sciences Corporation Recent Developments
6 North America
6.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Dynamics
11.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends
11.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Drivers
11.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Challenges
11.4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
